CVI Holdings’s Blueprint Medicines BPMC Stock Holding History

CVI Holdings’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200,000	Closed	-$16M	–	64
2019 Q1	$16M	Buy	+200,000	New	+$14.8M	15.16%	2

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CVI Holdings's BPMC Position: Q2 2019 in Review

CVI Holdings sold out of Blueprint Medicines (BPMC) in Q2 2019, closing a stake of 200,000 shares — an estimated $16M sold.

CVI Holdings first reported a position in BPMC in Q1 2019 and held it in 1 quarter. The position peaked at $16M in Q1 2019. 220 funds tracked by Wall St. Rank hold BPMC as of Q2 2019.

CVI Holdings reported no remaining Blueprint Medicines position as of Q2 2019 after selling out during the quarter.
CVI Holdings sold 200,000 Blueprint Medicines shares in Q2 2019, an estimated $16M.
CVI Holdings first reported a position in Blueprint Medicines in Q1 2019 and held it in 1 quarter.
CVI Holdings's Blueprint Medicines position peaked at $16M in Q1 2019.
220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2019.

Based on CVI Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.